Who is sponsoring NCT06289998?

NCT06289998 is sponsored by Rege Nephro Co., Ltd..

What drugs are being tested in NCT06289998?

Interventions in NCT06289998: Tamibarotene, Placebo.

What condition does NCT06289998 study?

NCT06289998 studies Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Is NCT06289998 still recruiting?

NCT06289998 is currently active, enrolled. Last updated 3 April 2025.

Last reviewed 2025-04-03 · How we verify

NCT06289998

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase IIa Clinical Trial of Tamibarotene in Patients With Autosomal Dominant Polycystic Kidney Disease

Active, enrolled Phase 2 Last updated 3 April 2025

What this trial tests

Phase 2 trial testing Tamibarotene in Autosomal Dominant Polycystic Kidney Disease (ADPKD) in 70 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

22 December 2023

Primary endpoint
1 December 2025

1 December 2025

Quick facts

Lead sponsor	Rege Nephro Co., Ltd.
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	70
Start date	22 December 2023
Primary completion	1 December 2025
Estimated completion	1 December 2025
Sites	8 locations across Japan

Drugs / interventions tested

Tamibarotene — full drug profile →
Placebo

Conditions studied

Autosomal Dominant Polycystic Kidney Disease (ADPKD) — all drugs for Autosomal Dominant Polycystic Kidney Disease (ADPKD) →

Sponsor

Rege Nephro Co., Ltd.

Who can join

Adults 26 to 55, any sex, with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Changes in TKV from baseline
Time frame: 52 Week after administration of Investigational Product
TKV

Sponsor's own description

Clinical trial of tamibarotene in patients with Autosomal Dominant Polycystic Kidney Disease

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Interventions for preventing the progression of autosomal dominant polycystic kidney disease.
St Pierre K, Cashmore BA, Bolignano D, Zoccali C, et al · · 2024 · cited 7× · PMID 39356039 · DOI 10.1002/14651858.cd010294.pub3

Verify or expand the search:

Other trials of Tamibarotene

Trials testing the same drug.

NCT06085638 — Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myel · Phase 1, PHASE2 · withdrawn
NCT04905407 — Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) · Phase 2 · terminated
NCT04797780 — Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome · Phase 3 · terminated
NCT02807558 — A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplas · Phase 2 · completed

Other recruiting trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Currently open trials in the same condition.

NCT07161037 — Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) · Phase 2 · recruiting
NCT06747572 — Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease · active not recruiting
NCT07355114 — Robotic vs Open Nephrectomy for ADPKD · active not recruiting
NCT07535385 — RADIOLOGICAL AND CLINICAL EVALUATION OF RENAL EMBOLIZATION USING EVOH IN DIALYSIS PATIENTS WITH AUTOSOMAL DOMINANT POLYC · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06289998 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rege Nephro Co., Ltd.
Last refreshed: 3 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06289998.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing